Vaxess Technologies today filed an SEC Form D to confirm the sale of $2 million in debt, options, warrants or other rights to buy securities.
According to the filing, three investors contributed to the new notice offering, which made its first sale on Monday, March 22, 2021, before reaching its total offering amount of $2 million today.
Cambridge, Mass.-based Vaxess did not make the offering in connection with a business combination transaction, such as a merger, acquisition or exchange offer. The company had not intended for it to last more than a year, as it took just four days.
The company did not list an intended use of proceeds. Vaxess develops a pipeline of proprietary MIMIX therapies, including ones for infectious diseases like COVID-19 and flu.
MIMIX, through just minutes of wear-time, enables the sustained release of treatments in the skin over minutes to as long as months. The company’s biomaterials technologies are based on silk, with the material’s unique properties offering a strong building block for biomaterial construction.